Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy
PP-1 demonstrates dual-target inhibitory activity against both the PD-1/PD-L1 immune checkpoint and tubulin polymerization, underscoring its potential as a promising lead compound for the development of next-generation dual-functional anticancer agents.
Authors
- Zhenhong Su (ORCID: https://orcid.org/0009-0009-0011-9910)
- Juan Du (ORCID: https://orcid.org/0000-0001-8190-3524)
- Yingxing Zhou
- Xiao Ying Yao
- Xinyi He
- Shayu An
- Lu Wang
- Jingwei Ding
Institutions
- Wuhan Polytechnic University (CN)
- Wuchang University of Technology (CN)
- Hubei Polytechnic University (CN)
- Huangshi Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.3389/fphar.2026.1740903
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00